From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
Plantamajoside is an orally active phenylpropanoid glycoside. Plantamajoside can be isolated from Plantago asiatica L.(Plantaginaceae). Plantamajoside inactivates NF-κB, PI3K/akt, induces Apoptosis, and improves Autophagy. Plantamajoside regulates MAPK, integrin-linked kinase/c-Src. Plantamajoside inhibits multiple cancers, improves lung and kidney damage. Plantamajoside has neuroprotective and anti-inflammatory effects.
For research use only. We do not sell to patients.
Plantamajoside is an orally active phenylpropanoid glycoside. Plantamajoside can be isolated from Plantago asiatica L.(Plantaginaceae). Plantamajoside inactivates NF-κB, PI3K/akt, induces Apoptosis, and improves Autophagy. Plantamajoside regulates MAPK, integrin-linked kinase/c-Src. Plantamajoside inhibits multiple cancers, improves lung and kidney damage. Plantamajoside has neuroprotective and anti-inflammatory effects[1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19].
In Vitro
Plantamajoside (1-800 µg/mL, 24 h-2 weeks) inhibits proliferation, stemness, and migration, and initiates apoptosis in 95D cells and dose-dependently suppresses the survival of 95D cells[3].
Plantamajoside (10 µM, 1-24 h) from Plantago asiatica modulates human umbilical vein endothelial cell dysfunction by glyceraldehyde-induced AGEs via MAPK/NF-κB[4].
Plantamajoside (10-40 µM, 24 h) inhibits high glucose-induced oxidative stress, inflammation, and extracellular matrix accumulation in rat glomerular mesangial cells HBZY-1 through the inactivation of Akt/NF-κB pathway[5].
Plantamajoside (5-120 µM 48 h) alleviates hypoxia-reoxygenation injury through integrin-linked kinase/c-Src/Akt and the mitochondrial apoptosis signaling pathways in H9c2 myocardial cells[6].
Plantamajoside (10-20 µM, 12-48 h) inhibits hypoxia-induced migration and invasion of human cervical cancer cells (SiHa and CaSki) through blocking the NF-κB and PI3K/akt pathways[7].
Plantamajoside (20-320 μg/mL, 24 h) ameliorates TGFβ2-induced autophagy, epithelial–mesenchymal transition and inflammatory processes in human lens epithelial cells (hLECs)[8].
Plantamajoside (20-160 μg/mL, 48 h) inhibits proliferation, migration, invasion and induces apoptosis in activated HSC-T6 cell[9].
Plantamajoside (20-160 μg/mL, 24-72 h) inhibits the invasion, migration and viability of malignant melanoma cells A2058[10].
Plantamajoside (2.5-40 μg/mL, 7 days) promotes metformin-induced apoptosis, autophagy and proliferation arrest of liver cancer cells via suppressing Akt/GSK3β signaling[11].
Plantamajoside (31.25-500 μg/mL, 12-48 h) inhibits breast cancer cells (MDA-MB-231) growth by decreasing the activity of matrix metalloproteinase-9 and -2[12].
Plantamajoside (10-80 μM, 24 h) protects H9c2 cells against hypoxia/reoxygenation-induced injury through regulating the akt/Nrf2/HO-1 and NF-κB signaling pathways[13].
Plantamajoside (20-160 g/mL) inhibits HCC cells progression through regulating cell viability, apoptosis, migration, invasion and PI3K/AKT pathway[14].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Exhibited significantly lower viability than the control group (100 µg/mL).
In Vivo
Plantamajoside (20-80 mg/kg) promotes the recovery of neurological function and protects the tissue structure of the spinal cord after ASCI in a rat model of acute spinal cord injury[15].
Plantamajoside (25-100 mg/kg, i.p., 24 h) alleviates acute sepsis-induced organ dysfunction through inhibiting the TRAF6/NF-κB axis in mice[16].
Plantamajoside (10-40 mg/kg, p.o., 4 weeks) has protective activities against Cd-induced renal injury in rats[17].
Plantamajoside (25-100 mg/kg, i.p., three times at 6, 12, 18 h) ameliorates lipopolysaccharide-induced acute lung injury via suppressing NF-κB and MAPK activation in mice[18].
Plantamajoside (20-80 mg/kg, i.p., once a day for 4 weeks) modulates immune dysregulation and hepatic lipid metabolism in rats with nonalcoholic fatty liver disease via AMPK/Nrf2 elevation[19].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model:
Acute sepsis C57BL/6 male mice model by caecal ligation and perforation (CLP)[16]
Dosage:
25, 50, 100 mg/kg
Administration:
Intraperitoneal injection (i.p.), 24 h
Result:
Extended survival in CLP model.
Improved acute sepsis-triggered organ damage.
Alleviated acute sepsis-triggered apoptosis.
Relieved acute sepsis-triggered inflammatory response.
Improved acute sepsis-triggered organ damage via mediating the TRAF6/NF-κB pathway.
Improved acute sepsis-triggered apoptosis and inflammation via regulating the TRAF6/NF-κB pathway.
DMSO : 100 mg/mL (156.11 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Preparing Stock Solutions
ConcentrationSolventMass
1 mg
5 mg
10 mg
1 mM
1.5611 mL
7.8053 mL
15.6106 mL
5 mM
0.3122 mL
1.5611 mL
3.1221 mL
10 mM
0.1561 mL
0.7805 mL
1.5611 mL
View the Complete Stock Solution Preparation Table
*Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles. Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day. The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
This protocol yields a clear solution of ≥ 0.83 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μLDMSO stock solution (8.3 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
This protocol yields a clear solution of ≥ 0.83 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μLDMSO stock solution (8.3 mg/mL) to 900 μLCorn oil, and mix evenly.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
Dosage
mg/kg
Animal weight (per animal)
g
Dosing volume (per animal)
μL
Number of animals
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO+
%
+
%
Tween-80
+
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO,
. All of co-solvents are available by MedChemExpress (MCE).
, Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration:
mg/mL
Method for preparing stock solution:
mg
drug dissolved in
μL
DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take
μL DMSO stock solution, add
μL .
μL , mix evenly, next add
μL Tween 80, mix evenly, then add
μL Saline.
Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution
If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
*Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles. Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.
Powered by Bioz
